{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:51:42Z","timestamp":1782139902248,"version":"3.54.5"},"reference-count":22,"publisher":"Norwegian Medical Association","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.17.0706","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T09:49:22Z","timestamp":1534931362000},"source":"Crossref","is-referenced-by-count":4,"title":["Anticoagulant-associated adverse drug reactions in 2013\u201315"],"prefix":"10.4045","volume":"138","author":[{"given":"Anne Katrine","family":"Eek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Oddvar","family":"Str\u00f8m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gine","family":"Bakkeh\u00f8i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Stenberg-Nilsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"ref=1","unstructured":"Connolly\u00a0SJ, Ezekowitz\u00a0MD, Yusuf\u00a0S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139\u201351. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19717844&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa0905561"},{"key":"ref=2","unstructured":"Granger\u00a0CB, Alexander\u00a0JH, McMurray\u00a0JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21870978&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1107039"},{"key":"ref=3","unstructured":"Patel\u00a0MR, Mahaffey\u00a0KW, Garg\u00a0J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21830957&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1009638"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Outes\u00a0A, Su\u00e1rez-Gea\u00a0ML, Lecumberri\u00a0R et al. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag 2014; 10: 627\u201339. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25404858&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2147%2FVHRM.S50543","DOI":"10.2147\/VHRM.S50543"},{"key":"ref=5","unstructured":"Informasjon om warfarin og de direkte virkende perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apixaban. Nasjonal r\u00e5dgivende spesialistgruppe innen antikoagulasjon. Oslo: Helsedirektoratet, 2015. https:\/\/helsedirektoratet.no\/Lists\/Publikasjoner\/Attachments\/433\/Informasjon-om-warfarin-og-de-perorale-antikoagulasjonsmidlene-dabigatran-rivaroksaban-og-apixaban-IS-2050-Fullversjon.pdf (13.1.2016)."},{"key":"ref=6","unstructured":"Guideline on good pharmacovigilance practices (GVP) \u2013 Module VI \u2013 Management and reporting of adverse reactions to medicinal products (Rev 1). European Medicines Agency, 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/09\/WC500172402.pdf (2.5.2018)"},{"key":"ref=7","unstructured":"Harg\u00a0P, Lislevand\u00a0H, Buajordet\u00a0I et al. Bivirkningsrapportering og legemiddeloverv\u00e5king. Tidsskr Nor L\u00e6geforen 2003; 123: 331\u20132. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12640902&dopt=Abstract"},{"key":"ref=8","unstructured":"Myhr K. G5 Bivirkninger og legemiddeloverv\u00e5king. Norsk Legemiddelh\u00e5ndbok 2016. http:\/\/legemiddelhandboka.no\/Generelle\/93635 (25.1.2017)."},{"key":"ref=9","unstructured":"Bivirkningsrapport for 2011. Oslo: Statens Legemiddelverk, 2012. https:\/\/legemiddelverket.no\/Documents\/Bivirkninger%20og%20sikkerhet\/Rapporter%20og%20oversikter\/%C3%85rsrapporter\/%C3%85rsrapport%20Bivirkninger%202011.pdf (9.2.2018)."},{"key":"ref=10","unstructured":"Breen\u00a0AB, Vaskinn\u00a0TE, Reikvam\u00a0A et al. Warfarinbehandling og bl\u00f8dninger. Tidsskr Nor L\u00e6geforen 2003; 123: 1835\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12830257&dopt=Abstract"},{"key":"ref=11","unstructured":"World Health Organization \u2013 Uppsala Monitoring Centre. Common concepts and terms in pharmacovigilance. https:\/\/www.who-umc.org\/safer-use-of-medicines\/safer-use-of-medicines-the-basics\/common-concepts-and-terms\/ (2.5.2018)."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Urbaniak\u00a0AM, Str\u00f8m\u00a0BO, Krontveit\u00a0R et al. Prescription patterns of non-vitamin k oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012\u20132015: a study from the Norwegian prescription database. Drugs Aging 2017; 34: 635\u201345. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28710707&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs40266-017-0476-4","DOI":"10.1007\/s40266-017-0476-4"},{"key":"ref=13","unstructured":"Stenberg-Nilsen H. Tilleggsskjema \u2013 bivirkninger av antikoagulantia. https:\/\/relis.no\/Bivirkninger\/Nytt_om_bivirkninger\/2013\/Tilleggsskjema_bivirkninger_av_antikoagulantia\/ (23.3.2017)."},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m\u00a0M, Mj\u00f6rndal\u00a0T, Dahlqvist\u00a0R et al. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol 2000; 56: 729\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11214784&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs002280000202","DOI":"10.1007\/s002280000202"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Pillans\u00a0PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol 2008; 1: 695\u2013705. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24422739&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1586%2F17512433.1.5.695","DOI":"10.1586\/17512433.1.5.695"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m\u00a0M, Mj\u00f6rndal\u00a0T, Dahlqvist\u00a0R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004; 13: 483\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15269932&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fpds.962","DOI":"10.1002\/pds.962"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Al-Khalili\u00a0F, Lindstr\u00f6m\u00a0C, Benson\u00a0L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin 2016; 32: 779\u201385. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26765366&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1185%2F03007995.2016.1142432","DOI":"10.1185\/03007995.2016.1142432"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Saraf\u00a0K, Morris\u00a0PD, Garg\u00a0P et al. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgrad Med J 2014; 90: 520\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25085900&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fpostgradmedj-2014-132605","DOI":"10.1136\/postgradmedj-2014-132605"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Halvorsen\u00a0S, Ghanima\u00a0W, Fride Tvete\u00a0I et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017; 3: 28\u201336. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27680880&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fehjcvp%2Fpvw031","DOI":"10.1093\/ehjcvp\/pvw031"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Granada\u00a0J, Uribe\u00a0W, Chyou\u00a0PH et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36: 2242\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11127467&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0735-1097(00)00982-7","DOI":"10.1016\/S0735-1097(00)00982-7"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Kundu\u00a0A, Sardar\u00a0P, Chatterjee\u00a0S et al. Minimizing the risk of bleeding with NOACs in the elderly. Drugs Aging 2016; 33: 491\u2013500. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27174293&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs40266-016-0376-z","DOI":"10.1007\/s40266-016-0376-z"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Moore\u00a0TJ, Cohen\u00a0MR, Mattison\u00a0DR. Dabigatran, bleeding, and the regulators. BMJ 2014; 349: g4517. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25056265&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbmj.g4517","DOI":"10.1136\/bmj.g4517"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Bivirkninger ved bruk av antikoagulasjonsmidler i 2013\u201315"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:16:17Z","timestamp":1781702177000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2018\/08\/originalartikkel\/bivirkninger-ved-bruk-av-antikoagulasjonsmidler-i-2013-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,8,21]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.17.0706","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]}}}